Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
EKR Therapeutics Raises Over $13 Million in a Series C Financing Round From New and Existing Investors
August 31st, 2007
EKR Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing, and commercializing proprietary therapeutics to enhance patient quality-of-life in the acute care setting, announced that it successfully raised over $13 million through the private placement of Series C preferred shares. This financing round was led by Quaker BioVentures, a new investor in EKR. Quaker is a Philadelphia-based venture capital firm with approximately $500 million under management focused on investing in life science companies. Also participating were existing EKR investors NewSpring Capital, based in Radnor, Pa. and Short Hills, N.J., and ESP Equity Partners, a...
Source: Drug Week (2007-08-31)
|
